Efficacy and Safety of Selumetinib in Pediatric Patients With Neurofibromatosis Type 1: A Systematic Review and Meta-analysis.
Hwang J, Yoon HM, Lee BH, Kim PH, Kim KW.
Neurology. 2022 Mar 1;98(9):e938-e946. doi: 10.1212/WNL.0000000000013296. Epub 2022 Jan 11.
PMID:35017312
Topical delivery of mitogen-activated protein kinase inhibitor binimetinib prevents the development of cutaneous neurofibromas in neurofibromatosis type 1 mutant mice.